Natan Melamed

Tel Aviv Sourasky Medical Center — Israel

Medicine · Health Sciences

1h-index6citations14works0.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(12), Protein Degradation and Inhibitors(3), Management of metastatic bone disease(2), Peptidase Inhibition and Analysis(2), Spine and Intervertebral Disc Pathology(1)

Publications14 total

Talquetamab Induces Deep Responses in Heavily Pre-Treated Patients with Systemic Light-Chain Amyloidosis
2026Open Access
Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes
Cancers·2026Open Access
Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network
Blood·2025Open Access
Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease is Associated with Favorable Outcomes
SSRN Electronic Journal·2025Open Access
Treatment Modalities and Outcomes of Multiple Myeloma Patients with Spinal Cord Compression: A Single Center Experience
Blood·2024
The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of Treatment
Cancers·2024· 1 citedOpen Access
Smoldering Multiple Myeloma Progressing to Active Multiple Myeloma Vs De-Novo Active Multiple Myeloma - a Comparison of Disease Characteristics, Organ Involvement and Outcomes in a Real-Life Multicenter Retrospective Cohort Study
Blood·2023· 3 citedOpen Access
A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)
Blood·2023Open Access
Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma
Blood·2023
POSTER: MM-362 Multiple Myeloma Oligosecretory Relapse: A Cross-Sectional Historical Cohort Study
Clinical Lymphoma Myeloma & Leukemia·2023
MM-362 Multiple Myeloma Oligosecretory Relapse: A Cross-Sectional Historical Cohort Study
Clinical Lymphoma Myeloma & Leukemia·2023
P966: SMOLDERING MULTIPLE MYELOMA (MM) PROGRESSING TO ACTIVE MM DURING FOLLOW-UP: REDUCED BONE DISEASE AND IMPROVED PROGRESSION-FREE AND OVERALL SURVIVAL COMPARED TO DE-NOVO NEWLY DIAGNOSED MM
HemaSphere·2023· 1 citedOpen Access
P942: MULTIPLE MYELOMA OLIGOSECRETORY RELAPSE- A CROSS SECTIONAL HISTORICAL COHORT STUDY
HemaSphere·2023Open Access
A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)
Blood·2022· 1 cited

Frequent Co-authors

Yaël C. Cohen(14), Tamir Shragai(13), Iuliana Vaxman(10), Svetlana Trestman(10), Irit Avivi(9), Gil Fridberg(7), Inbar Cohen(6), Pia Raanani(5), Efrat Luttwak(5), Moshe E. Gatt(4), Renana Robinson(3), Tomer Ziv‐Baran(3), Irit Avivi Mazza(3), Itai Zamir(3), Ronit Shmuel(3), Angela Dispenzieri(3), Morie A. Gertz(3), Evgeni Chubar(2), Chezi Ganzel(2), Hila Magen(2)